Evidence map›Paper›PMID 40964038›Full record

ArticleResearch square2025

Engineering B cells to Express Fully Customizable Antibodies with Enhanced Fc Functions.

Chun Huang, Atishay Mathur, Chan-Hua Chang, Xiaoli Huang, Hsu-Yu Chen, Zachary B Davis, Karla O'Dell, Elizabeth A Shuman, Raymond W Kung, Geoffrey L Rogers and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Chun HuangDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Atishay MathurDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID 0009-0002-6872-944X
Chan-Hua ChangDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Xiaoli HuangDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Hsu-Yu ChenDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
Zachary B DavisDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Karla O'DellDepartment of Otolaryngology-Head & Neck Surgery, University of Southern California, Los Angeles, California, USA.
Elizabeth A ShumanDepartment of Otolaryngology-Head & Neck Surgery, University of Southern California, Los Angeles, California, USA.
Raymond W KungDepartment of Otolaryngology-Head & Neck Surgery, University of Southern California, Los Angeles, California, USA.
Geoffrey L RogersDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-9183-1269
Paula M CannonDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.ORCID 0000-0003-0059-354X

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
Primate CoreU19HL156247 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CANNON, PAULA M, KIEM, HANS-PETER · 2020 to 2024
$14.6M
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodiesR01AI167003 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Adi Barzel, Paula M Cannon · 2022 to 2026
$3.5M
Engineering B cells for enhanced HIV controlF30AI186662 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Atishay Mathur · 2024 to 2026
$164k
NCI NIH HHS P30 CA014089NHLBI NIH HHS U19 HL156247NIAID NIH HHS F30 AI186662NIAID NIH HHS R01 AI167003NIAID NIH HHS UM1 AI164561
6 · The paper itself

Abstract

Genome editing within the constant region of the immunoglobulin Heavy chain locus (

Identifiers

PMID40964038
PMCPMC12440107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.